(Q33389069)

English

Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

0 references

anticoagulation

1 reference

based on heuristic

inferred from title

thrombocytopenia

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

heparin-induced thrombocytopenia

1 reference

based on heuristic

inferred from title

Paul R Reynolds

object named as

Paul R Reynolds

4

0 references

author name string

Narayanam V Rao

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Brian Argyle

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Xiaoyu Xu

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jeanine M Walenga

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Margaret Prechel

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Glenn D Prestwich

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Robert B MacArthur

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Bradford B Walters

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

John R Hoidal

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Thomas P Kennedy

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

7 April 2010

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

American Journal of Physiology - Cell Physiology

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

299

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

C97-110

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer

1 reference

https://api.crossref.org/works/10.1152%2FAJPCELL.00009.2010

21 January 2018

Characterization of growth factor-binding structures in heparin/heparan sulfate using an octasaccharide library

1 reference

https://api.crossref.org/works/10.1152%2FAJPCELL.00009.2010

21 January 2018

Heparin regulates vascular endothelial growth factor165-dependent mitogenic activity, tube formation, and its receptor phosphorylation of human endothelial cells. Comparison of the effects of heparin and modified heparins

1 reference

https://api.crossref.org/works/10.1152%2FAJPCELL.00009.2010

21 January 2018

Acidic polyamino acids inhibit human eosinophil granule major basic protein toxicity. Evidence of a functional role for ProMBP

1 reference

https://api.crossref.org/works/10.1152%2FAJPCELL.00009.2010

21 January 2018

Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis

1 reference

https://api.crossref.org/works/10.1152%2FAJPCELL.00009.2010

21 January 2018

Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis

1 reference

https://api.crossref.org/works/10.1152%2FAJPCELL.00009.2010

21 January 2018

The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment

1 reference

https://api.crossref.org/works/10.1152%2FAJPCELL.00009.2010

21 January 2018

Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

1 reference

https://api.crossref.org/works/10.1152%2FAJPCELL.00009.2010

21 January 2018

Neuroprotective properties of glycosaminoglycans: potential treatment for neurodegenerative disorders

1 reference

https://api.crossref.org/works/10.1152%2FAJPCELL.00009.2010

21 January 2018

Heparin is an adhesive ligand for the leukocyte integrin Mac-1 (CD11b/CD1).

1 reference

https://api.crossref.org/works/10.1152%2FAJPCELL.00009.2010

21 January 2018

The extracellular region of the receptor for advanced glycation end products is composed of two independent structural units.

1 reference

https://api.crossref.org/works/10.1152%2FAJPCELL.00009.2010

21 January 2018

Function of pulmonary M2 muscarinic receptors in antigen-challenged guinea pigs is restored by heparin and poly-L-glutamate

1 reference

https://api.crossref.org/works/10.1152%2FAJPCELL.00009.2010

21 January 2018

Advanced glycation end products: sparking the development of diabetic vascular injury

1 reference

https://api.crossref.org/works/10.1152%2FAJPCELL.00009.2010

21 January 2018

Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE)

1 reference

https://api.crossref.org/works/10.1152%2FAJPCELL.00009.2010

21 January 2018

RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides

1 reference

https://api.crossref.org/works/10.1152%2FAJPCELL.00009.2010

21 January 2018

The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system

1 reference

https://api.crossref.org/works/10.1152%2FAJPCELL.00009.2010

21 January 2018

Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).

1 reference

https://api.crossref.org/works/10.1152%2FAJPCELL.00009.2010

21 January 2018

The effect of low molecular weight heparin on survival in patients with advanced malignancy

1 reference

https://api.crossref.org/works/10.1152%2FAJPCELL.00009.2010

21 January 2018

Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents

1 reference

https://api.crossref.org/works/10.1152%2FAJPCELL.00009.2010

21 January 2018

S100B and S100A6 differentially modulate cell survival by interacting with distinct RAGE (receptor for advanced glycation end products) immunoglobulin domains

1 reference

https://api.crossref.org/works/10.1152%2FAJPCELL.00009.2010

21 January 2018

Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism

1 reference

https://api.crossref.org/works/10.1152%2FAJPCELL.00009.2010

21 January 2018

Novel drug development opportunities for heparin.

1 reference

https://api.crossref.org/works/10.1152%2FAJPCELL.00009.2010

21 January 2018

Solution structure of the variable-type domain of the receptor for advanced glycation end products: new insight into AGE-RAGE interaction

1 reference

https://api.crossref.org/works/10.1152%2FAJPCELL.00009.2010

21 January 2018

Perspectives series: cell adhesion in vascular biology. Role of PSGL-1 binding to selectins in leukocyte recruitment

1 reference

https://api.crossref.org/works/10.1152%2FAJPCELL.00009.2010

21 January 2018

RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin

1 reference

https://api.crossref.org/works/10.1152%2FAJPCELL.00009.2010

21 January 2018

Structural features in heparin that interact with VEGF165 and modulate its biological activity

1 reference

https://api.crossref.org/works/10.1152%2FAJPCELL.00009.2010

21 January 2018

A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin

1 reference

https://api.crossref.org/works/10.1152%2FAJPCELL.00009.2010

21 January 2018

Heparin derivatives as inhibitors of BACE-1, the Alzheimer's beta-secretase, with reduced activity against factor Xa and other proteases.

1 reference

https://api.crossref.org/works/10.1152%2FAJPCELL.00009.2010

21 January 2018

Neutrophil serine proteases: specific regulators of inflammation

1 reference

https://api.crossref.org/works/10.1152%2FAJPCELL.00009.2010

21 January 2018

Activation of platelets by heparin-induced thrombocytopenia antibodies in the serotonin release assay is not dependent on the presence of heparin

1 reference

https://api.crossref.org/works/10.1152%2FAJPCELL.00009.2010

21 January 2018

Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications

1 reference

https://api.crossref.org/works/10.1152%2FAJPCELL.00009.2010

21 January 2018

Potential role of high-mobility group box 1 in cystic fibrosis airway disease.

1 reference

https://api.crossref.org/works/10.1152%2FAJPCELL.00009.2010

21 January 2018

The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses

1 reference

https://api.crossref.org/works/10.1152%2FAJPCELL.00009.2010

21 January 2018

Differential metastasis inhibition by clinically relevant levels of heparins--correlation with selectin inhibition, not antithrombotic activity

1 reference

https://api.crossref.org/works/10.1152%2FAJPCELL.00009.2010

21 January 2018

Nonanticoagulant heparin inhibits NF-kappaB activation and attenuates myocardial reperfusion injury

1 reference

https://api.crossref.org/works/10.1152%2FAJPCELL.00009.2010

21 January 2018

Newer insights on the mechanism of heparin-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1152%2FAJPCELL.00009.2010

21 January 2018

Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins

1 reference

https://api.crossref.org/works/10.1152%2FAJPCELL.00009.2010

21 January 2018

Tissue destruction by neutrophils

1 reference

https://api.crossref.org/works/10.1152%2FAJPCELL.00009.2010

21 January 2018

Structural basis for pattern recognition by the receptor for advanced glycation end products (RAGE).

1 reference

https://api.crossref.org/works/10.1152%2FAJPCELL.00009.2010

21 January 2018

Heparin-binding protein (HBP/CAP37): A missing link in neutrophil-evoked alteration of vascular permeability

1 reference

https://api.crossref.org/works/10.1152%2FAJPCELL.00009.2010

21 January 2018

Identifiers

10.1152/AJPCELL.00009.2010

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33389069&oldid=1628073011"